Ray Dirks has been a respected analyst on Wall Street for decades. Ray has written two books,” The Great Wall Street Scandal” and “Heads You Win, Tails You Win”, published by McGraw-Hill and Bantam Books respectively. Dirks opened his own securities analysis firm after gaining much attention in the financial press during the 1970s and 1980s. Ray earned his place in the history books while working as a securities research analyst. He got a tip from a disgruntled employee of a company called Equity Funding that this firm had built its business model upon massive commercial and accounting fraud. Most research analysts on Wall Street took Equity Funding's numbers at face value, and recommended the stock. Dirks, however, began his own investigation, found the tip credible, then warned both his firm's top institutional clients (who sold out their positions) and the SEC. He also tried, unsuccessfully, to interest The Wall Street Journal in the story. It turned out that the tip was right, and Equity Funding eventually collapsed in a manner that would prefigure some of the scandals that have been seen on the Street today.
Sramana Mitra is the founder of One Million by One Million (1M/1M), a global virtual accelerator that aims to help one million entrepreneurs globally to reach $1 million in revenue and beyond. She is a Silicon Valley entrepreneur and strategy consultant, she writes the blog Sramana Mitra On Strategy, and is author of the Entrepreneur Journeys book series and Vision India 2020. From 2008 to 2010, Mitra was a columnist for Forbes. As an entrepreneur CEO, she ran three companies: DAIS, Intarka, and Uuma. Sramana has a master’s degree in electrical engineering and computer science from the Massachusetts Institute of Technology. Full bio can be found at http://www.sramanamitra.com/bio/
I graduated top of my class with a degree in management with a concentration in finance. While I work in a finance capacity in the non-profit world, I have been following the market and trading daily since I was sixteen years old. I have always loved analyzing individual businesses and trends in their stock price, and finding trading/investing opportunities that the overall market has not yet recognized.
My fascination with the market began when I put $3,000 I had saved into my very first stock trade, selling 20 minutes later for a $200 profit. I was sixteen, and it was love at first sight. I have closely followed the markets ever since, and have traded/invested in hundreds of stocks. My professional career has also involved starting a couple of businesses, and managing a few others. While I prefer short term trades based on technical analysis, I enjoy performing fundamental analysis on business models that I can easily understand.
My goal for my Seeking Alpha articles and technical analysis blog posts is to show people some of the items I analyze when making investment and trading decisions, in a concise and easy to understand manner.
Please follow me on Seeking Alpha for updates on my latest articles!
Please follow me on Twitter for daily market/trades commentary: https://twitter.com/BostonTrades
Please visit my blog for daily technical charts: http://kisstechnicals.blogspot.com/
Roland Rick Perry is the Managing Director of Institutional Analyst Inc. (IA), an independent investment research and investor relations firm, as well as editor of nine industry specific investment reviews. One of the best one mile runners to come out of the Chicago area, he attended Southern Illinois University, Loyola of Chicago and UCLA on track scholarships, achieving an Olympic Qualifying time in the early eighties, right in time for the Olympic boycott in 1980.
Roland began his career on the floor of the Chicago Board Options Exchange (CBOE) as a runner in 1974. He worked for a number of well respected investment banking firms such as Merrill Lynch, Paine Webber, AG Becker Paribas and Drexel Burnham Lambert, prior to launching his own firm in 1995.
He is the founder of the Chicago Stock & Bond Club, Morgan & Weed and Blank Check Capital Corp., which recently participated in Wall Street’s first “Ultra Mini™” blank check offering, as President of Life Sciences Opportunities Inc., which successfully merged with Beverly Hills based “Dr Tattoff” the leading Tattoo removal company in the U.S., with over 250,000 treatments on more than 25,000 patients.
Founded in 2004 and headquartered in Beverly Hills, CA, Dr. Tattoff clinics are currently located throughout Southern California, Texas, Arizona and Georgia. Soon to go public (sooner or later) after completion of necessary required steps.
Featured by the New York Times, the Los Angeles Times, Us Weekly, In Touch, People, CNN, ABC, LA Ink, Dr. 90210 and numerous other print, on-air and online media outlets, Dr. Tattoff is widely recognized as a leading provider of laser tattoo removal and laser hair removal.
SEC filings BamSEC: https://www.bamsec.com/companies/1294157/dr-tattoff-inc
Mr Perry has been quoted and/or interviewed in the New York Times, the Los Angeles Times, CBS MarketWatch, South China Morning Post, the London Register, the UK Register and featured in Australia's ABC televised broadcast Lateline, and in a featured segment piece on National Enquirer TV.
IA is a leading publisher of news, perspective and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm works with small-cap companies which have products and/or services which can best be described as "best of breed." To align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in their client companies.
Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY.
Our sites include:
Internet Stock Review.com
Patent Stock Review.com (on hold)
Alternative Energy Stock Review.com
Private Equity Stock Review.com
Marine Exploration Stock Review
IA Special Situation Research.ning.com
Biotech Stock Review.com
Restaurant Stock Review.com
National Stock Review.com
Stem Cell Stock Review.com
Beverage Stock Review.com
Blanket disclaimer for all of our postings: Important Distinction #1. First and foremost the Watch List is just that. A watch list. It is not a buy list. Meaning that there will be no buys or sale recommendations issued by the various Reviews. If this was a buy list, you can rest assured that we would crank up our Public Relations arm into high gear, full speed ahead and damn the torpedoes to make everyone know just how brilliant we were when we issued the original Watch List in 1998 with the average stock gaining 157% the first year.. Interviews on CNBC, articles in Barron's and accolades in the Wall Street Journal--the only thing we love more than money is praise and fame--but it just isn't going to happen. What the Reviews are...is a "news aggregation service". With the advent of the Internet, everyone knows what that term means. What it means to us is the following: We will follow the progress of as many industry specific related publicly traded stocks as humanly possible (The large, the small and the minuscule) and advise you of when they have reported news. As a subscriber to any of our Reviews, this means you will be able to broadly follow an entire industry right from a single e-mail. We will report who released news and point (with hyper links) to where the news can be found. We try to use Yahoo! Finance and Seeking Alpha as extensively as possible so we don't send you all over cyberspace. We love Yahoo and Seeking Alpha, you will too. Any decisions as to buy or sell however, are strictly up to you. Which leads to important distinction #2. How do we get paid? The Reviews are owned by a Public Relations firm (Institutional Analyst Inc.) that specializes in getting (or creating) coverage for publicly traded companies. As such, is important to note that anytime we say anything about a company, it is because the company is a client of our parent company, or because we would like them to be a client of our parent company. In a nutshell, you can throw out any thoughts of us being even a little bit impartial. It just ain't gonna happen. We love everyone. Institutional Analyst Inc. is an independent research and investor-relations consulting firm that publishes investment-research reports such as The Reviews on independently selected companies. While it is its intent to identify and research companies that it believes might prove to be profitable investments, The Review is not liable for any investment decisions by its readers. Neither The Reviews nor any report published by Institutional Analyst Inc., represent a solicitation to buy or sell the securities discussed within the report. It is strongly recommended that any purchase or sale decisions be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. The information contained herein is provided as an information service only and is based upon sources deemed reliable, but not guaranteed by The Reviews. Past performance of previously featured companies does not guarantee the future success of any currently featured or mentioned company. The information contained herein is subject to change without notice, and The Reviews assumes no responsibility to update the information in this or any report published. Use of this or any report published by The Review may be subject to the applicable rules of certain self-regulatory organizations and the securities mentioned herein, which are traded Over The Counter, and may not be cleared for sale in certain states. Institutional Analyst Inc and/or its employees, officers, affiliates or members of their families may have long or short positions in any of the securities discussed in this or other reports published herein (and/or options or warrants relating thereto) and may purchase and or sell these securities, options or warrants from time to time in the open market or otherwise. Institutional Analyst Inc may derive compensation through research services and subscriptions and/or investor-relations consulting from the companies featured or mentioned in its reports. Write or call Institutional Analyst Inc for disclosure details as required by Rule 17b as it relates to individual issues. Institutional Analyst Inc., In no event shall The Reviews report be liable for direct, indirect, incidental or consequential damages resulting from the use of this information. The Reviews shall be indemnified and held harmless from any actions, claims, proceedings or liabilities with respect to the information herein. Institutional Analyst Inc is not a securities
broker-dealer, investment advisor or a securities exchange and is not registered as such with the Securities and Exchange commission nor any state securities regulation authority. Readers of this e-mail newsletter should recognize that the Reviews are only providing a delivery service to electronically transmit information to potential investors. In this respect, the Reviews are no different than the provider of any other delivery service such as the United States Post Office or any other express delivery service. Accordingly, investors should be aware that the Reviews have not evaluated nor investigated any of the companies listed in this e-mail to determine their merit or the risk of investment in any such company. The Reviews do not endorse any company listed herein and the Reviews do not represent that the information contained in any offering documents states all material facts or does not omit a material fact necessary to make the statements therein not misleading. firstname.lastname@example.org
For specific company disclaimer, please visit any of our websites about disclaimers where we have been compensated are on each blog right-up front in big print, on each research report written and in the general disclaimer section. We have nothing to hide, our disclaimers are everywhere. As the majority of our compensation is in restricted stock, the better our clients perform (which we have no control over), the better we are compensated and vice versa. This is in sharp contrast to firms which only accept cash as compensation, and who really couldn't care less how the stock performs, as long as their check keeps coming in. We believe this puts us on the same page as shareholders and our readers, because we are in fact shareholders.
BioGroup Team (BGT) is a self-organized panel of professionals with a shared interest in trading and investing in the healthcare and life sciences sectors. Our experts’ editorial team is comprised of individuals with extensive background in research, science, economics and trading in the biotechnology / health sectors.
Our main focus is identifying and analyzing cutting edge biotechnology companies that are under or over-valued. We obtain information from public sources that we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our aim is to deliver a succinct analysis which is clear and detailed enough to provide the reader with a better understanding of our findings and conclusions.
Lowenthal Capital Partners (LCP) has joined Arrow Loop Research to deliver a value-based investing newsletter called Arrow Loop Research's Actionable Ideas for Maximizing Returns. Sign up for a free trial here.
LCP is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Boulder Law School.
Arrow Loop Research formed as a partnership between LCP, Dr. Paul Price, and Market Shadows (Paul is a managing partner of Market Shadows.)
Paul writes about stocks, options and the market every weekday on Real Money Pro, a subscription site on TheStreet.com. Paul has been a speaker at the International Traders Expo in New York City and the Options and Forex Expo in Las Vegas. He also gives investment seminars for subscribers of TheStreet's multiple subscription sites. Dr. Price is a featured contributor on Market Shadows.com, GuruFocus.com and TalkMarkets.com.
Paul followed his passion for the stock market when he gave up his career as a dentist to join Merrill Lynch back in April of 1987. Paul feels that he is “living the dream” of many investors. He stopped “going to work” when he turned 50 (in the year 2000) and has been living well from his investment returns ever since.
Paul enjoys sharing the accumulated market wisdom he’s gained from years in the markets. He loves analyzing companies and picking individual stocks. According to Paul, once you know what equities to buy, option writing (selling covered calls and/or naked puts) just flows naturally. They serve as ways to impose investment discipline and create income while providing an extra margin of safety versus plain vanilla share ownership. Paul’s articles stand out for their unique graphics which are packed with information which distills our TMI (too much information) world into easy to understand, and actionable advice.
GuruFundPicks.com offers top buy & sell picks based on the collective or Consensus Picks' of over 330 of our hand-picked top hedge & mutual fund managers, incl. 78 legendary or guru fund managers, 27 of the world's largest or mega funds, 165 sector-focused funds (in gold, biotech, tech, energy, consumer, finance & REITs), 59 billionaires, 54 new masters and 40 tiger, 52 shareholder activist and our Winners Circle Top 100 Performing Hedge Fund Managers (updated quarterly). We offer market-beating tools and services including Consensus Picks' DIY Tools, Top 20 Small-Cap and Top 30 All-Cap Long/Short Newsletters based on the Consensus Picks system, and Trade Alert Services for Self & Auto-Trading. All of our services have beaten market averages by wide margins. See our website GuruFundPicks.com for the latest performance numbers, or contact us at support@GuruFundPicks.com.
The two authors are co-managers of a family partnership long/short equity fund since 2001, that have a successful track record in trading primarily small-cap aggressive growth companies based on a fundamental valuation analysis of current news, including quarter reports, guidance, biotech clinical study results and other news. The junior partner is a self-taught private investor with a Business degree from the New York University's Leonard N. Stern School of Business and the senior partner has an MBA from the University of Virginia Darden School of Business, including prior MS & BS (Engg.) degrees, and with experience in business strategy consulting to large fortune 100 companies.
We are generally sector and market-cap agnostic, identifying opportunities using a 'stock picking' bottom-up, fundamentals-based, valuation-driven approach. However, we find most opportunities in the small-cap space, in technology & healthcare sectors, with some also found often in the consumer, energy & basic materials sectors.
Follow us on Seeking Alpha and Twitter (@GuruFundPicks), and connect with us on LinkedIn (http://www.linkedin.com/in/manishbabla)
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Cory Renauer is a long-term dividend-growth investor. He is always on the lookout for well managed companies with predictable earnings growth, significant economic advantages over their competitors, and a commitment to increasing shareholder value.
My firm provides investment products and solutions for institutions and individual investors. I take particular attention to small and mid-cap companies in emerging markets. I like to research and trade good ideas; both long and short; with other experienced traders.
Zvi Bar-Kochba is a legal and financial trust consultant based on Wall Street, and a leading authority on trust administration and estate planning. Zvi provides advisory services for trusts and beneficiaries. Zvi provides consulting expert services regarding prudent investing, securities regulations and evaluations of potential fiduciary liability. Publications here are written by agents, representatives and individuals associated with or contracted by the author or publisher. No articles or discussions here shall constitute a legal, fiduciary or advisory role, but solely act as informative press and/or a starting point from which further discussion may follow. Comments are welcome, as are questions.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
MarketScanners is a newsletter featuring Market Scans and Trading Ideas based on many different types of fundamentals scans, market analytics and technical analysis. Coupled with fundamentals and news catalysts, some of the plays we highlight for investors tend to move quickly and make great candidates for momentum traders and others seeking quick picks based on solid analysis and research.
Some companies featured in our newsletter pay MarketScanners for research, analysis, articles and distribution. Our reports contain forward-looking statements relating to the developments of the featured company’s products, services, future operating results and the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
Since we are often compensated in shares or cash for our services, investors should evaluate the information on the Site with that in mind and should always perform their own independent analysis.
Team StockMatusow.com research and writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about 17 years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Additionally, Dan is a Scientist and inventor. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunoncology focused approaches. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team.
Places you can follow Scott are:
Places to follow Dan are:
Ray Dirks has been a respected analyst on Wall Street for decades. Ray has written two books,” The Great Wall Street Scandal” and “Heads You Win, Tails You Win”, published by McGraw-Hill and Bantam Books respectively.
Dirks opened his own securities analysis firm after gaining much attention in the financial press during the 1970s and 1980s.
Ray earned his place in the history books while working as a securities research analyst. He got a tip from a disgruntled employee of a company called Equity Funding that this firm had built its business model upon massive commercial and accounting fraud. Most research analysts on Wall Street took Equity Funding's numbers at face value, and recommended the stock.
Dirks, however, began his own investigation, found the tip credible, then warned both his firm's top institutional clients (who sold out their positions) and the SEC. He also tried, unsuccessfully, to interest The Wall Street Journal in the story. It turned out that the tip was right, and Equity Funding eventually collapsed in a manner that would prefigure some of the scandals that have been seen on the Street today.